Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02556736 · ClinicalTrials.gov registry record · Phase 1
AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa
A Phase 1 study of Advanced Retinitis Pigmentosa, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 4
- Study locations
NCT02556736: Completed Phase 1 study of Advanced Retinitis Pigmentosa, sponsored by AbbVie.
NCT02556736 is a Phase 1 study of Advanced Retinitis Pigmentosa that has completed, run by AbbVie. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02556736, a Phase 1 study of Advanced Retinitis Pigmentosa, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 4
- Study locations
Study Summary
All participants in phase 1 and phase 2a had hand motion visual acuity or worse. If efficacy was demonstrated from phase 1, better vision subjects could be enrolled; however, efficacy was not demonstrated.
Primary Outcome
An adverse event is any untoward medical occurrence in a subject or clinical investigation patient administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Conditions Studied
Interventions
- DRUG AGN-151597
Study Locations (4)
California
- University of California San Francisco - Mission Bay /ID# 235717 - San Francisco
Kentucky
- Cincinnati Eye Institute- Edgewood /ID# 236713 - Edgewood
North Carolina
- Duke Eye Center /ID# 235715 - Durham
Texas
- Retina Foundation of the Southwest /ID# 235199 - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-12-14 |
| Est. Completion | 2024-10-21 |
| Phase | Phase 1 |
What the finished NCT02556736 record still lists
NCT02556736 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Advanced Retinitis Pigmentosa appearing as the primary indexed condition, and to 1 intervention - of which AGN-151597 is the first listed.
NCT02556736 reports a single indexed study location in California, Kentucky, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02556736 about?
NCT02556736 is a clinical study titled "AGN-151597 (Formerly RST-001) Phase I/II Trial for Advanced Retinitis Pigmentosa". All participants in phase 1 and phase 2a had hand motion visual acuity or worse. If efficacy was demonstrated from phase 1, better vision subjects could be enrolled; however, efficacy was not demonstrated.
What is the current status of trial NCT02556736?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2015-12-14. Estimated completion is 2024-10-21.
What conditions does trial NCT02556736 study?
This clinical trial studies the following conditions: Advanced Retinitis Pigmentosa.
What interventions are being tested in trial NCT02556736?
The interventions under investigation include: AGN-151597 (DRUG).
Who is sponsoring clinical trial NCT02556736?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02556736 being conducted?
This trial has 4 study locations across California, Kentucky, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02556736's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy